These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 36266386)

  • 1. Urine-derived exosomal PSMA is a promising diagnostic biomarker for the detection of prostate cancer on initial biopsy.
    Wang CB; Chen SH; Zhao L; Jin X; Chen X; Ji J; Mo ZN; Wang FB
    Clin Transl Oncol; 2023 Mar; 25(3):758-767. PubMed ID: 36266386
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Urine Exosomal AMACR Is a Novel Biomarker for Prostate Cancer Detection at Initial Biopsy.
    Jin X; Ji J; Niu D; Yang Y; Tao S; Wan L; Xu B; Chen S; Wang F; Chen M
    Front Oncol; 2022; 12():904315. PubMed ID: 35795046
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Urinary exosomal prostate-specific antigen is a noninvasive biomarker to detect prostate cancer: Not only old wine in new bottles.
    Wei C; Chen X; Ji J; Xu Y; He X; Zhang H; Mo Z; Wang F
    Int J Cancer; 2023 Apr; 152(8):1719-1727. PubMed ID: 36454163
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Establishment and prospective validation of an SUV
    Jiao J; Kang F; Zhang J; Quan Z; Wen W; Zhao X; Ma S; Wu P; Yang F; Guo W; Yang X; Yuan J; Shi Y; Wang J; Qin W
    Theranostics; 2021; 11(17):8396-8411. PubMed ID: 34373749
    [No Abstract]   [Full Text] [Related]  

  • 5. Exosomal Prostate-Specific Membrane Antigen (PSMA) and Caveolin-1 as Potential Biomarkers of Prostate Cancer-Evidence from Serbian Population.
    Matijašević Joković S; Korać A; Kovačević S; Djordjević A; Filipović L; Dobrijević Z; Brkušanin M; Savić-Pavićević D; Vuković I; Popović M; Brajušković G
    Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542507
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Novel Urine Exosomal lncRNA Assay to Improve the Detection of Prostate Cancer at Initial Biopsy: A Retrospective Multicenter Diagnostic Feasibility Study.
    Li Y; Ji J; Lyu J; Jin X; He X; Mo S; Xu H; He J; Cao Z; Chen X; Xu Y; Wang L; Wang F
    Cancers (Basel); 2021 Aug; 13(16):. PubMed ID: 34439239
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Urinary microRNA-based signature improves accuracy of detection of clinically relevant prostate cancer within the prostate-specific antigen grey zone.
    Salido-Guadarrama AI; Morales-Montor JG; Rangel-Escareño C; Langley E; Peralta-Zaragoza O; Cruz Colin JL; Rodriguez-Dorantes M
    Mol Med Rep; 2016 Jun; 13(6):4549-60. PubMed ID: 27081843
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnostic Performance of Prostate-specific Membrane Antigen Positron Emission Tomography-targeted biopsy for Detection of Clinically Significant Prostate Cancer: A Systematic Review and Meta-analysis.
    Kawada T; Yanagisawa T; Rajwa P; Sari Motlagh R; Mostafaei H; Quhal F; Laukhtina E; Aydh A; König F; Pallauf M; Pradere B; Ceci F; Baltzer PAT; Hacker M; Rasul S; Karakiewicz PI; Araki M; Nasu Y; Shariat SF
    Eur Urol Oncol; 2022 Aug; 5(4):390-400. PubMed ID: 35715320
    [TBL] [Abstract][Full Text] [Related]  

  • 9. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor-Derived Exosomal Long Noncoding RNAs as Promising Diagnostic Biomarkers for Prostate Cancer.
    Wang YH; Ji J; Wang BC; Chen H; Yang ZH; Wang K; Luo CL; Zhang WW; Wang FB; Zhang XL
    Cell Physiol Biochem; 2018; 46(2):532-545. PubMed ID: 29614511
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nanoscale flow cytometry to distinguish subpopulations of prostate extracellular vesicles in patient plasma.
    Padda RS; Deng FK; Brett SI; Biggs CN; Durfee PN; Brinker CJ; Williams KC; Leong HS
    Prostate; 2019 May; 79(6):592-603. PubMed ID: 30680751
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer at Initial Biopsy.
    McKiernan J; Donovan MJ; O'Neill V; Bentink S; Noerholm M; Belzer S; Skog J; Kattan MW; Partin A; Andriole G; Brown G; Wei JT; Thompson IM; Carroll P
    JAMA Oncol; 2016 Jul; 2(7):882-9. PubMed ID: 27032035
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Additive Diagnostic Value of Prostate-specific Membrane Antigen Positron Emission Tomography Computed Tomography to Multiparametric Magnetic Resonance Imaging Triage in the Diagnosis of Prostate Cancer (PRIMARY): A Prospective Multicentre Study.
    Emmett L; Buteau J; Papa N; Moon D; Thompson J; Roberts MJ; Rasiah K; Pattison DA; Yaxley J; Thomas P; Hutton AC; Agrawal S; Amin A; Blazevski A; Chalasani V; Ho B; Nguyen A; Liu V; Lee J; Sheehan-Dare G; Kooner R; Coughlin G; Chan L; Cusick T; Namdarian B; Kapoor J; Alghazo O; Woo HH; Lawrentschuk N; Murphy D; Hofman MS; Stricker P
    Eur Urol; 2021 Dec; 80(6):682-689. PubMed ID: 34465492
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    Liu C; Liu T; Zhang Z; Zhang N; Du P; Yang Y; Liu Y; Yu W; Li N; Gorin MA; Rowe SP; Zhu H; Yan K; Yang Z
    J Nucl Med; 2020 Sep; 61(9):1314-1319. PubMed ID: 32034111
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protocol for the PRIMARY clinical trial, a prospective, multicentre, cross-sectional study of the additive diagnostic value of gallium-68 prostate-specific membrane antigen positron-emission tomography/computed tomography to multiparametric magnetic resonance imaging in the diagnostic setting for men being investigated for prostate cancer.
    Amin A; Blazevski A; Thompson J; Scheltema MJ; Hofman MS; Murphy D; Lawrentschuk N; Sathianathen N; Kapoor J; Woo HH; Chalasani V; Rasiah K; van Leeuwen PJ; Tang R; Cusick T; Stricker P; Emmett L
    BJU Int; 2020 Apr; 125(4):515-524. PubMed ID: 31957122
    [TBL] [Abstract][Full Text] [Related]  

  • 16. How to make clinical decisions to avoid unnecessary prostate screening in biopsy-naïve men with PI-RADs v2 score ≤ 3?
    Zhang Y; Zeng N; Zhang F; Huang Y; Tian Y
    Int J Clin Oncol; 2020 Jan; 25(1):175-186. PubMed ID: 31473884
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A molecular signature of PCA3 and ERG exosomal RNA from non-DRE urine is predictive of initial prostate biopsy result.
    Donovan MJ; Noerholm M; Bentink S; Belzer S; Skog J; O'Neill V; Cochran JS; Brown GA
    Prostate Cancer Prostatic Dis; 2015 Dec; 18(4):370-5. PubMed ID: 26345389
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnostic performance of
    Zhang J; Shao S; Wu P; Liu D; Yang B; Han D; Li Y; Lin X; Song W; Cao M; Zhang J; Kang F; Qin W; Wang J
    Eur J Nucl Med Mol Imaging; 2019 Apr; 46(4):908-920. PubMed ID: 30635755
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Prospective Adaptive Utility Trial to Validate Performance of a Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer in Patients with Prostate-specific Antigen 2-10ng/ml at Initial Biopsy.
    McKiernan J; Donovan MJ; Margolis E; Partin A; Carter B; Brown G; Torkler P; Noerholm M; Skog J; Shore N; Andriole G; Thompson I; Carroll P
    Eur Urol; 2018 Dec; 74(6):731-738. PubMed ID: 30237023
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection of High-grade Prostate Cancer Using a Urinary Molecular Biomarker-Based Risk Score.
    Van Neste L; Hendriks RJ; Dijkstra S; Trooskens G; Cornel EB; Jannink SA; de Jong H; Hessels D; Smit FP; Melchers WJ; Leyten GH; de Reijke TM; Vergunst H; Kil P; Knipscheer BC; Hulsbergen-van de Kaa CA; Mulders PF; van Oort IM; Van Criekinge W; Schalken JA
    Eur Urol; 2016 Nov; 70(5):740-748. PubMed ID: 27108162
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.